- Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions
-
Maurer K, Michener C, Mahdi H, Rose PG
- KMID: 2413426
- J Gynecol Oncol.
- 2017 Jul;28(4):e38.
- doi: 10.3802/jgo.2017.28.e38
OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR. METHODS: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologic malignancy... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer
-
Lee KW, Kim JH, Yun T, Song EK, Na II, Shin H, Oh SY, Choi IS, Oh DY, Kim DW, Im SA, Kim TY, Lee JS, Heo DS, Bang YJ, Kim NK
- KMID: 1785799
- J Korean Med Sci.
- 2007 Sep;22(Suppl):S115-S121.
- doi: 10.3346/jkms.2007.22.S.S115
This study was performed to evaluate the efficacy and toxicity of low-dose paclitaxel/cisplatin chemotherapy in patients with metastatic or recurrent gastric cancer that had failed 5-fluorouracil/platinum-based chemotherapy. Thirty-two patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase II Study of Paclitaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
-
Hwang J, Cho SH, Shim HJ, Lee SR, Ahn JS, Yang DH, Kim YK, Lee JJ, Kim HJ, Chung IJ
- KMID: 1785814
- J Korean Med Sci.
- 2008 Aug;23(4):586-591.
- doi: 10.3346/jkms.2008.23.4.586
This phase II study evaluated the efficacy and safety of combination chemotherapy with paclitaxel, cisplatin, and 5-fluorouracil (5-FU) in advanced gastric cancer. Patients with histologically confirmed gastric adenocarcinoma were eligible... -
- CITED
-
- Close
- SHARE
-
- Close
- Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer
-
Fujiwara S, Terai Y, Tsunetoh S, Sasaki H, Kanemura M, Ohmichi M
- KMID: 2345922
- J Gynecol Oncol.
- 2015 Oct;26(4):311-319.
- doi: 10.3802/jgo.2015.26.4.311
OBJECTIVE: There is no research regarding the appropriate antiemetic agents for female patients, especially those receiving moderately emetogenic chemotherapy (MEC). We evaluated the antiemetic efficacy of a combination of 5-HT3... -
- CITED
-
- Close
- SHARE
-
- Close
- Combined Treatment of an Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy (Paclitaxel) for Murine Fibrosarcoma
-
Choi GS, Lee MH, Kim SK, Kim CS, Lee HS, Im MW, Kil HY, Seong DH, Lee JR, Kim WC, Lee MG, Song SU
- KMID: 2428301
- Yonsei Med J.
- 2005 Dec;46(6):835-842.
A novel combined treatment of conventional chemotherapy with an intratumoral injection of syngeneic dendritic cells (DCs) has emerged as a potent cancer treatment strategy. In this study, we evaluated the... -
- CITED
-
- Close
- SHARE
-
- Close
- A Less Intensive Combination of Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer Patients who Have Aged 60 Years or More and Has a Poor Performance Status
-
Min YJ, Ahn JJ, Noh YJ, Cha HJ, Suh JH, Jung JP, Park CR, Jeong AK, Park JH, Lee KM
- KMID: 759697
- Korean J Intern Med.
- 2004 Jun;19(2):109-113.
BACKGROUND: The aim of this study was to evaluate the response, survival, and toxicities of a less intensive combination of paclitaxel and carboplatin, which is used in advanced non-small cell... -
- CITED
-
- Close
- SHARE
-
- Close
- Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
-
Cho SH, Chung IJ, Song SY, Yang DH, Byun JR, Kim YK, Lee JJ, Na KJ, Kim HJ
- KMID: 1712743
- J Korean Med Sci.
- 2005 Aug;20(4):618-623.
- doi: 10.3346/jkms.2005.20.4.618
Although various combinations of chemotherapy regimens have been tried for patients with esophageal cancer, their duration of survival is extremely poor. In this study, we investigated the safety and clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer
-
Kim JH, Lee KW, Kim YH, Lee KH, Oh DY, Kim J, Yang SH, Im SA, Choi SH, Bang YJ
- KMID: 1713950
- J Korean Med Sci.
- 2010 May;25(5):684-690.
- doi: 10.3346/jkms.2010.25.5.684
The purpose of our study was to determine the most accurate analytic method to define in vitro chemosensitivity, using clinical response as reference standard in prospective clinical trial, and to... -
- CITED
-
- Close
- SHARE
-
- Close
- Anti-inflammatory Effect of Abciximab-Coated Stent in a Porcine Coronary Restenosis Model
-
Hong YJ, Jeong MH, Lee SR, Hong SN, Kim KH, Park HW, Kim JH, Kim W, Ahn Y, Cho JG, Park JC, Kang JC
- KMID: 1713284
- J Korean Med Sci.
- 2007 Oct;22(5):802-809.
- doi: 10.3346/jkms.2007.22.5.802
The aim of this study was to examine the anti-inflammatory effect of abciximab-coated stent in a porcine coronary overstretch restenosis model. Ten abciximab-coated stents, ten sirolimus-eluting stents (SES), and ten... -
- CITED
-
- Close
- SHARE
-
- Close
- Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study
-
Coccolini , Campanati , Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, Lotti M, Magnone S, Napoli J, Rossetti D, De Iaco P, Frigerio L, Pinna A, Runnebaum , Ansaloni L
- KMID: 2158803
- J Gynecol Oncol.
- 2015 Jan;26(1):54-61.
- doi: 10.3802/jgo.2015.26.1.54
OBJECTIVE: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been recently reported with favorable oncological outcomes as treatment of advanced epithelial ovarian cancer (EOC). The aim of this study... -
- CITED
-
- Close
- SHARE
-
- Close
- Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients
-
Mabuchi S, Isohashi F, Okazawa M, Kitada F, Maruoka S, Ogawa K, Kimura T
- KMID: 2413856
- J Gynecol Oncol.
- 2017 Jan;28(1):e15.
- doi: 10.3802/jgo.2017.28.e15
OBJECTIVE: To evaluate the efficacy and toxicity of paclitaxel plus carboplatin (TC)-based concurrent chemoradiotherapy (CCRT) followed by consolidation chemotherapy in the International Federation of Gynecology and Obstetrics (FIGO) stage IIIB/IVA... -
- CITED
-
- Close
- SHARE
-
- Close
- A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study
-
Kim U, Lee CH, Jo JH, Lee HW, Choi YJ, Son JW, Lee SH, Park JS, Shin DG, Kim YJ, Jeong MH, Cho MC, Bae JH, Lee JH, Kang TS, Jung KT, Jung KH, Lee SW, Cho JH, Kim W, Hur SH, Kim KS, Park HS, Kim MH, Hwang JY, Kim DI, Kim TI
- KMID: 1777657
- J Korean Med Sci.
- 2013 Nov;28(11):1609-1614.
- doi: 10.3346/jkms.2013.28.11.1609
We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease... -
- CITED
-
- Close
- SHARE
-
- Close
- Cost-Effectiveness of Drug-Eluting vs. Bare-Metal Stents in Patients with Coronary Artery Disease from the Korean National Health Insurance Database
-
Lee S, Baek K, Chun K
- KMID: 2070200
- Yonsei Med J.
- 2014 Nov;55(6):1533-1541.
- doi: 10.3349/ymj.2014.55.6.1533
PURPOSE: The aim of this study was to evaluate the cost-effectiveness of the use of drug-eluting stents (DESs), as compared with bare-metal stents (BMSs) in Korea. MATERIALS AND METHODS: A retrospective... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Characteristics of Coronary Drug-Eluting Stent Fracture: Insights from a Two-Center DES Registry
-
Park KW, Park JJ, Chae IH, Seo JB, Yang HM, Lee HY, Kang HJ, Cho YS, Yeon TJ, Chung WY, Koo BK, Choi DJ, Oh BH, Park YB, Kim HS
- KMID: 1777976
- J Korean Med Sci.
- 2011 Jan;26(1):53-58.
- doi: 10.3346/jkms.2011.26.1.53
Stent fracture (SF) has been implicated as a risk factor for in-stent restenosis, but its incidence and clinical characteristics are not well established. Therefore we investigated the conditions associated with... -
- CITED
-
- Close
- SHARE
-
- Close
- Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02)
-
Ohnishi S, Watari H, Kanno M, Ohba Y, Takeuchi S, Miyaji T, Oyamada S, Nomura E, Kato H, Sugiyama T, Asaka M, Sakuragi N, Yamaguchi , Uezono Y, Iwase S
- KMID: 2413215
- J Gynecol Oncol.
- 2017 Sep;28(5):e44.
- doi: 10.3802/jgo.2017.28.e44
OBJECTIVE: Rikkunshito, an herbal medicine, is widely prescribed in Japan for the treatment of anorexia and functional dyspepsia, and has been reported to recover reductions in food intake caused by... -
- CITED
-
- Close
- SHARE
-
- Close
- Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer
-
Lim MC, Yoo HJ, Song YJ, Seo SS, Kang S, Kim SH, Yoo CW, Park SY
- KMID: 2413432
- J Gynecol Oncol.
- 2017 Jul;28(4):e48.
- doi: 10.3802/jgo.2017.28.e48
OBJECTIVE: To investigate the survival outcomes in patients with bulky stage IIIC and IV ovarian cancer, treated by primary debulking surgery (PDS) and selective use of neoadjuvant chemotherapy (NAC) according... -
- CITED
-
- Close
- SHARE
-
- Close
